{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:09:17Z","timestamp":1788822557077,"version":"build-2803163510"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["18\/151"],"award-info":[{"award-number":["18\/151"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to investigate the cost\u2010effectiveness of low\u2010dose colchicine prophylaxis for preventing gout flares when starting allopurinol using the \u201cstart\u2010low go\u2010slow\u201d approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants with gout, fulfilling the American College of Rheumatology recommendations for starting urate\u2010lowering therapy and with serum urate \u22650.36 mmol\/L (6 mg\/dL), were randomly allocated (1:1) to either colchicine (0.5 mg daily) or placebo for six months with a further six\u2010month follow\u2010up. All participants received allopurinol, with monthly increase in dose to achieve target urate &lt;0.36 mmol\/L. The primary outcomes were incremental cost\u2010effectiveness at the 6\u2010month and 1\u2010year follow\u2010up from the health system perspective, measured by incremental net monetary benefit (INMB) at a willingness\u2010to\u2010pay threshold equivalent to gross domestic product per capita.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two hundred participants were randomized to either colchicine (n = 100) or placebo (n = 100). Mean costs were higher in the colchicine group over both six months and one year (adjusted mean difference $1,848 [95% confidence interval (CI) \u2212$321 to $4,017] and $2,282 [95% CI \u2212$173 to $4,737], respectively). Quality\u2010adjusted life years were slightly higher in the colchicine group over six months (adjusted mean difference 0.008 [95% CI \u22120.020 to 0.035]) but lower over one year (\u22120.015 [95% CI \u22120.039 to 0.010]). Treatment with colchicine was not found to be cost\u2010effective at either 6 months or 12 months (INMB \u2212$1,373 [95% CI \u2212$4,287 to $1,542] and \u2212$3,191 [95% CI \u2212$6,274 to \u2212$107], probability of cost\u2010effectiveness 17.7% and 1.5%, respectively). Similar results were obtained from a societal perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Six months of low\u2010dose colchicine prophylaxis when starting allopurinol using the \u201cstart\u2010low go\u2010slow\u201d approach is unlikely to be cost\u2010effective over 12 months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.25631","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T06:25:33Z","timestamp":1755584733000},"page":"337-343","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost\u2010Effectiveness of Low\u2010Dose Colchicine Prophylaxis When Starting Allopurinol Using the \u201cStart\u2010Low Go\u2010Slow\u201d Approach for Gout: Evidence From a Noninferiority Randomized Double\u2010Blind Placebo\u2010Controlled Trial"],"prefix":"10.1002","volume":"78","author":[{"given":"Yana","family":"Pryymachenko","sequence":"first","affiliation":[{"name":"Centre for Musculoskeletal Outcomes Research, University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8505-8081","authenticated-orcid":false,"given":"Ross","family":"Wilson","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Outcomes Research, University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-4476","authenticated-orcid":false,"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[{"name":"University of Auckland  Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6468-7284","authenticated-orcid":false,"given":"J. Haxby","family":"Abbott","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Outcomes Research, University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-2912","authenticated-orcid":false,"given":"Lisa","family":"Stamp","sequence":"additional","affiliation":[{"name":"University of Otago  Christchurch Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24180"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.01.008"},{"issue":"12","key":"e_1_2_7_5_1","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad GC","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224731"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211574"},{"key":"e_1_2_7_8_1","volume-title":"Pharmaceutical schedule","author":"Wilson K","year":"2018"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.0898"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02204-0"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39254"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czw096"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0606-1"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0585-2"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.741"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-45"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200523020-00002"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.117150"},{"key":"e_1_2_7_21_1","unstructured":"Statistics NZ.Earnings for people in paid employment by region sex age groups and ethnic groups.2021. Accessed June 9 2025.https:\/\/explore.data.stats.govt.nz\/vis?fs[0]=Economy%2C0%7CIncome%23CAT_INCOME%23&pg=0&fc=Economy&bp=true&snb=16&vw=tb&df[ds]=ds\u2010nsiws\u2010disseminate&df[id]=INC_INC_001&df[ag]=STATSNZ&df[vs]=1.0&dq=.98.98.98.98.&to[TIME]=false"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0193-3"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.944"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7654"},{"key":"e_1_2_7_25_1","unstructured":"R. Version 4.3.1. R Project for Statistical Computing;2023.http:\/\/www.R-project.org"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0227"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32158-5"},{"issue":"1","key":"e_1_2_7_28_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261940","article-title":"Model\u2010based cost\u2010effectiveness analyses comparing combinations of urate lowering therapy and anti\u2010inflammatory treatment in gout patients","volume":"17","author":"Laar CJ","year":"2022","journal-title":"PLoS One"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1211-y"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.4.437"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24357"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25486"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.25631","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.25631","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.25631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:00:57Z","timestamp":1778252457000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.25631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/acr.25631"],"URL":"https:\/\/doi.org\/10.1002\/acr.25631","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"2025-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}